StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.01−0.27 (-2.86%)

Close on Nov 18, 2026Market cap $579.84MP/E –Yield –

Cullinan Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Cullinan Therapeutics's net income for the twelve months ending Dec 31, 2025 was -$219.88M. For fiscal 2025 it was -$219.88M. The highest annual figure on record is $111.21M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$219.88M–
FY2024Dec 31, 2024-$167.38M–
FY2023Dec 31, 2023-$153.16M-237.7%
FY2022Dec 31, 2022$111.21M–
FY2021Dec 31, 2021-$65.57M–
FY2020Dec 31, 2020-$51.80M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$50.71M–
Q3 FY2025Sep 30, 2025-$50.61M–
Q2 FY2025Jun 30, 2025-$70.06M–
Q1 FY2025Mar 31, 2025-$48.50M–
Q4 FY2024Dec 31, 2024-$47.65M–
Q3 FY2024Sep 30, 2024-$40.56M–
Q2 FY2024Jun 30, 2024-$42.03M–
Q1 FY2024Mar 31, 2024-$37.15M–
Q4 FY2023Dec 31, 2023-$23.80M–
Q3 FY2023Sep 30, 2023-$39.18M–
Q2 FY2023Jun 30, 2023-$32.21M-118.4%
Q1 FY2023Mar 31, 2023-$57.96M–
Q4 FY2022Dec 31, 2022-$26.78M–
Q3 FY2022Sep 30, 2022-$24.80M–
Q2 FY2022Jun 30, 2022$174.90M–
Q1 FY2022Mar 31, 2022-$12.10M–
Q4 FY2021Dec 31, 2021-$32.51M–
Q3 FY2021Sep 30, 2021-$17.35M–
Q2 FY2021Jun 30, 2021-$15.64M–
Q1 FY2021Mar 31, 2021-$70.00K–
Q4 FY2020Dec 31, 2020-$28.35M–
Q3 FY2020Sep 30, 2020-$9.86M–
Q2 FY2020Jun 30, 2020-$8.62M–
Q1 FY2020Mar 31, 2020-$4.97M–

More Cullinan Therapeutics figures

See a number that looks wrong?